Trials / Active Not Recruiting
Active Not RecruitingNCT06280716
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase 3 Trial to Investigate the Efficacy and Safety of Lebrikizumab When Used With/Without Topical Corticosteroid Treatment in Participants With Moderate-To-Severe Atopic Dermatitis
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 301 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab with/without Topical Corticosteroid Treatment in Participants with Moderate-to-Severe Atopic Dermatitis. The study will last approximately 62 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Subcutaneous injection |
| DRUG | Lebrikizumab | Subcutaneous injection |
| DRUG | Topical Corticosteroid | Topical Corticosteroid |
Timeline
- Start date
- 2024-04-24
- Primary completion
- 2025-09-25
- Completion
- 2026-08-01
- First posted
- 2024-02-28
- Last updated
- 2025-10-15
Locations
46 sites across 2 countries: China, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06280716. Inclusion in this directory is not an endorsement.